European CHMP recommends paediatric license extension of blinatumomab (Blincyto) for acute lymphoblastic leukaemia (ALL)
The proposed license extension is as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy.
Source:
European Medicines Agency